Our Company
|
Burrill & Company Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has $1 billion under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report (www.burrillreport.com) and annual “State of the Industry” report. Burrill & Company has built a global enterprise raising capital and enacting deals around the world. The company has offices located in India (Mumbai), China/Taiwan (Shanghai/Taipei), Malaysia (Kuala Lumpur), the Middle East (Abu Dhabi/Dubai/Qatar/Saudi Arabia), Korea (Seoul), the European Union (London), Japan (Tokyo), and Latin America (Santiago/Chile, Buenos Aires/Argentina, and Sao Paolo and Rio de Janeiro/Brazil). The company’s global operations continue to be directed centrally from its offices in San Francisco by a talented, multi-cultural, multi-lingual team. (www.burrillandco.com) Kuwait Life Sciences Company Kuwait Life Sciences Company (KLSC) is a wholly owned company of National Technology Enterprises Company (NTEC), capitalized at USD 16.5 million, to act as its regional investment arm in healthcare and life sciences space. In turn, NTEC is fully owned by Kuwait Investment Authority (KIA) and was established in 2004 to act as a 'corporate venture capitalist' focused on international technology investments and be the gateway for sustainable transfer of emerging technologies to Kuwait and the Middle East region. NETC is uniquely positioned as a technology investor in the region and enjoys a broad network with venture capital funds, investment companies, industry leaders, research centers and governmental bodies. KLSC aims to create start up projects, invest in growing companies which exhibit novelty, possess a technological edge, have a sustainable business model, fulfill a compelling need or offer significant value to healthcare sector in Kuwait and Middle East. Via a joint venture style, KLSC can partner with multinational companies, regional investors and healthcare players to enrich technology investments locally and regionally. Clinically, among the highest priorities in the Arabian Gulf region are cardiovascular diseases, obesity, diabetes, and cancers such as breast, lung, colorectal, prostate, and leukemia. Infertility, osteoporosis, and dermatological conditions are also of concern. Strategically, KLSC continues to explore establishing platform services for clinical trials, and breakthrough technologies in the medical, diagnostic, laboratory, and imaging space. |